Saturday 17 October 2026 Export PETS’s income statement to Excel — free account

PetMed Express, Inc.

PETS Healthcare Pharmaceutical Retailers

PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025. In the quarter to June 2026, revenue fell 19.9%, EPS grew 83.0% and free cash flow grew 38.6%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.

1.20 0.02 −1.64%

Follow PETS

Alert me

Market cap: $26.4M
P/E: 0.0×
Fwd P/E: 24.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.40
Beneish M: −4.77
Dividend safety: 36/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 33.63%

Capital & Financial Ratios $m

Market Cap 26.44

Revenue 168.86

Net Income (29.28)

Free Cash Flow (27.77)

Net Debt (13.08)

Current Ratio 0.68

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 24.00

P/S ratio 0.15

P/B ratio 1.13

Past 5Y EPS Growth —

This Y EPS Growth 81.75%

Next Y EPS Growth 30.00%

Next Y revenue growth (16.66%)

Next 5Y EPS Growth 49.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.07%

10-year low 10-year high

P/B against its own 10 years 13.31%

10-year low 10-year high

EV/Sales against its own 10 years 2.48%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	0.90	0.30 0.30 0.30
2022	1.20	0.30 0.30 0.30 0.30
2021	1.18	0.28 0.30 0.30 0.30
2020	1.11	0.27 0.28 0.28 0.28
2019	1.08	0.27 0.27 0.27 0.27
2018	1.04	0.25 0.25 0.27 0.27
2017	0.79	0.19 0.20 0.20 0.20
2016	0.75	0.18 0.19 0.19 0.19

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	55	55	21	13
Receivables	3	2	2	2
Inventory	29	16	14	8
Other	—	—	—	—
	94	79	44	28

	2024	2025	2026	Q'26
Payables	37	24	21	12
ST’ Debt	—	—	—	—
Other	—	—	—	—
	72	63	52	41

Compound Annual Growth %

	10y	5y	3y
Sales	(2.67%)	(10.02%)	(10.24%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.02%)	(27.17%)	(35.92%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	41	—	—	—	—
’26	51	44	41	43	179
’25	66	58	52	51	227
’24	78	71	65	60	274
’23	70	65	59	53	248
’22	79	67	61	65	272
’21	96	75	66	66	304

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(8)	—	—	—	—
’26	(12)	(2)	(9)	(5)	(28)
’25	(9)	7	(1)	7	5
’24	1	(1)	(3)	7	4
’23	6	(1)	13	10	28
’22	0	1	9	9	18
’21	(11)	26	6	18	40

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(8)	—	—	—	—
’26	(14)	(5)	(9)	(5)	(33)
’25	(9)	6	(2)	5	0
’24	(1)	(2)	(4)	6	0
’23	5	(3)	12	8	23
’22	(1)	1	8	8	17
’21	(11)	25	6	18	38

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.28)	—	—	—	—
’26	(1.65)	(0.41)	(0.50)	(0.19)	(2.74)
’25	0.18	0.11	(0.03)	(0.56)	(0.30)
’24	(0.06)	0.03	(0.10)	(0.25)	(0.37)
’23	0.14	0.13	(0.01)	(0.01)	0.25
’22	0.22	0.31	0.21	0.18	1.04
’21	0.39	0.42	0.38	0.01	1.19

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	19.21	21.85	15.00	21.20	24.75	17.08	5.50	2.90	1.57	1.15	Analyst estimates 2027–2029 Powerpack
	High	50.90	57.80	27.80	42.89	57.00	29.53	22.64	7.79	5.58	3.70
People
People	Employees	187	187	199	214	219	212	302	287	173	189
	Revenue/emp, $m	1.33	1.46	1.42	1.33	1.39	1.28	0.82	0.96	1.31	0.95
Income, $m
Income, $m	Revenue	249	274	283	284	304	272	248	274	227	179
	Gross margin, %	31.83	35.72	33.63	28.60	27.77	28.26	30.90	30.93	30.46	28.05
	EBT	38	54	49	34	31	24	7	(6)	(1)	(57)
	EBT margin, %	15.22	19.65	17.33	11.93	10.19	8.88	3.01	(2.29)	(0.26)	(32.04)
	Net income	24	37	38	26	24	19	5	(7)	(6)	(57)
	Depreciation	1	2	2	2	2	3	4	7	8	37
Per share, $
Per share, $	Revenue	12.32	13.46	13.85	14.18	15.13	13.50	12.21	13.44	11.02	8.56
	Earnings	1.18	1.83	1.84	1.29	1.19	1.05	0.25	(0.37)	(0.30)	(2.74)
	Cash flow	2.33	1.84	2.21	1.94	2.00	0.92	1.37	0.21	0.23	(1.36)
	Capex	(0.52)	(0.03)	(0.03)	(0.12)	(0.12)	(0.09)	(0.26)	(0.22)	(0.25)	(0.22)
	Free cash flow	1.81	1.80	2.18	1.82	1.88	0.83	1.11	(0.01)	(0.02)	(1.58)
	Book value	4.61	5.69	6.58	6.49	7.04	6.12	5.42	4.74	4.13	1.38
	Shares, m	20	20	20	20	20	20	20	20	21	21
Valuation, ×
Valuation, ×	P/E	17.07	22.40	12.50	22.48	29.42	27.98	65.38	0.00	0.00	0.00
	P/S	1.64	3.06	1.67	2.03	2.32	1.91	1.33	0.35	0.38	0.27
	P/B	4.36	7.25	3.51	4.44	4.99	4.22	2.99	0.99	1.01	1.65
	EV/Sales	1.40	2.78	1.31	1.66	1.93	1.50	0.91	0.15	0.14	0.15
	EV/FCF	9.53	20.74	8.37	12.95	15.59	24.45	9.99	(207.00)	(79.94)	(0.80)
Cash, $m
Cash, $m	Operating cash flow	47	37	45	39	40	18	28	4	5	(28)
	Capex	(11)	(1)	(1)	(2)	(2)	(2)	(5)	(5)	(5)	(5)
	Free cash flow	37	37	45	37	38	17	23	0	0	(33)
Balance, $m
Balance, $m	Working capital	63	87	108	105	116	95	73	21	16	(8)
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	(59)	(78)	(101)	(104)	(119)	(111)	(104)	(55)	(55)	(21)
	Shareholders’ equity	93	116	135	130	141	123	110	97	85	29
Returns, %
Returns, %	ROA	23.46	30.11	26.09	16.69	13.95	10.19	2.96	(4.42)	(3.94)	(49.84)
	ROIC	67.64	86.22	84.50	73.76	84.57	122.73	64.32	(12.31)	(3.14)	(487.12)
	ROE	26.98	35.66	30.14	19.53	17.63	14.14	4.40	(7.22)	(6.90)	(100.45)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HITI High Tide Inc.	$228.2M	— (loss-making)	92.0×	+30.72% (above 0%: growing)	+800.00% (above 0%: growing)	−7.91% (below 0%: shrinking)	26.53%	4.38%	Compare
PETS PetMed Express, Inc.	$26.4M	— (loss-making)	24.0×	−19.86% (below 0%: shrinking)	n/m	+38.60% (above 0%: growing)	27.63%	(15.19%)
MEDS DataMeds AI, Inc	$12.8M	— (loss-making)	—	−77.15% (below 0%: shrinking)	n/m	−41.85% (below 0%: shrinking)	10.24%	(412.67%)	Compare
SCNX Scienture Holdings, Inc.	$5.6M	— (loss-making)	— (loss-making)	+3,235.92% (above 0%: growing)	n/m	−53.98% (below 0%: shrinking)	97.73%	(785.71%)	Compare
POM Pomdoctor Limited - Sponsored ADR	$5.0M	—	—	—	—	—	—	—	Compare
RDGT Ridgetech Inc.	$3.0M	— (loss-making)	— (loss-making)	+113.14% (above 0%: growing)	n/m	+4,848.31% (above 0%: growing)	22.81%	0.00%	Compare
MDVLQ MedAvail Holdings, Inc.	$2.9M	— (loss-making)	— (loss-making)	−25.41% (below 0%: shrinking)	n/m	+66.32% (above 0%: growing)	43.95%	(1,099.75%)	Compare
BIMI BIMI Holdings Inc.	$170.0K	— (loss-making)	—	−48.85% (below 0%: shrinking)	n/m	+28.06% (above 0%: growing)	4.57%	(124.83%)	Compare
Median of peers	$5.0M	—	—	+2.65%	—	+10.08%	24.67%	(268.75%)

All 8 Pharmaceutical Retailers stocks →

PetMed Express, Inc. (PETS) key facts

Concern: PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025.
PetMed Express, Inc. (PETS) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PETS traded at $1.20, a market capitalization of $26.4 million.
Return on equity was −100.5% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.40 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.